Exelixis and Pfizer drugs face off in kidney cancer
October 10, 2016 at 02:15 AM EDT
COPENHAGEN, Oct 10 (Reuters) - Exelixis' drug Cabometyx beat Pfizer's Sutent in a clinical study in metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.
